FloraStilbene: immunotherapy adjuvant for breast cancer DOI Open Access

Famela Ramos,

Santosh Kesari,

George Delgado

et al.

Journal of Stem Cell Research & Therapeutics, Journal Year: 2024, Volume and Issue: 9(1), P. 45 - 53

Published: Jan. 1, 2024

Despite significant advancements in therapeutic approaches to triple-negative breast cancer, treatments remain relatively ineffective once metastasis occurs. The introduction of immunotherapy has revolutionized oncological therapies, yet hurdles before its full potential can be realized. In this review, we examine immune escape mechanisms shared between pregnancy (the 'fetal allograft') and cancer. We discuss the use abortion-inducing agents context cancer immunotherapy, also provide rationale preliminary data on FloraStilbene™, a combination polyphenol antioxidant pterostilbene glucocorticoid receptor antagonist mifepristone, for stimulation anticancer immunity.

Language: Английский

Leveraging Single-Cell Multi-Omics to Decode Tumor Microenvironment Diversity and Therapeutic Resistance DOI Creative Commons
Hussein Sabit, Borros Arneth, Timothy M. Pawlik

et al.

Pharmaceuticals, Journal Year: 2025, Volume and Issue: 18(1), P. 75 - 75

Published: Jan. 10, 2025

Recent developments in single-cell multi-omics technologies have provided the ability to identify diverse cell types and decipher key components of tumor microenvironment (TME), leading important advancements toward a much deeper understanding how heterogeneity contributes cancer progression therapeutic resistance. These are able integrate data from molecular genomic, transcriptomic, proteomics, metabolomics studies cells at resolution scale that give rise full cellular complexity TME. Understanding complex sometimes reciprocal relationships among cells, CAFs, immune ECs has led novel insights into their immense functions, which can consequences on behavior. In-depth uncovered evasion mechanisms, including exhaustion T metabolic reprogramming response hypoxia cells. Single-cell also revealed resistance such as stromal cell-secreted factors physical barriers extracellular matrix. Future examining specific pathways targeting approaches reduce TME will likely lead better outcomes with immunotherapies, drug delivery, etc., for treatments. incorporate data, spatial micro-environments, translation personalized therapies. This review emphasizes provide TME, revealing reprogramming, influences. aim guide development targeted therapies, highlighting role diversity shaping behavior treatment outcomes.

Language: Английский

Citations

6
Frontiers in pancreatic cancer on biomarkers, microenvironment, and immunotherapy DOI Creative Commons

Baofa Yu,

Shengwen Shao, Wenxue Ma

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: unknown, P. 217350 - 217350

Published: Nov. 1, 2024

Pancreatic cancer remains one of the most challenging malignancies to treat due its late-stage diagnosis, aggressive progression, and high resistance existing therapies. This review examines latest advancements in early detection, therapeutic strategies, with a focus on emerging biomarkers, tumor microenvironment (TME) modulation, integration artificial intelligence (AI) data analysis. We highlight promising including microRNAs (miRNAs) circulating DNA (ctDNA), that offer enhanced sensitivity specificity for early-stage diagnosis when combined multi-omics panels. A detailed analysis TME reveals how components such as cancer-associated fibroblasts (CAFs), immune cells, extracellular matrix (ECM) contribute therapy by creating immunosuppressive barriers. also discuss interventions target these components, aiming improve drug delivery overcome evasion. Furthermore, AI-driven analyses are explored their potential interpret complex data, enabling personalized treatment strategies real-time monitoring response. conclude identifying key areas future research, clinical validation regulatory frameworks AI applications, equitable access innovative comprehensive approach underscores need integrated, outcomes pancreatic cancer.

Language: Английский

Citations

6
Dual roles of myeloid-derived suppressor cells in various diseases: a review DOI
Mahesh R. Nepal,

S. P. Shah,

Kyu‐Tae Kang

et al.

Archives of Pharmacal Research, Journal Year: 2024, Volume and Issue: 47(7), P. 597 - 616

Published: July 1, 2024

Language: Английский

Citations

5
MiR- 150 deletion promotes lung tumor growth by upregulating P-STAT3 and ROS in MDSCs DOI Creative Commons

Anqi X. Qin,

Hao Chen, Fan Xu

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: April 15, 2025

Language: Английский

Citations

0
The role of exosomes in bladder cancer immunotherapy DOI Creative Commons
Mohammad Mousaei Ghasroldasht, Piyush K. Agarwal

Journal of the National Cancer Center, Journal Year: 2025, Volume and Issue: unknown

Published: May 1, 2025

Language: Английский

Citations

0
Tumor-infiltrating myeloid cells; mechanisms, functional significance, and targeting in cancer therapy DOI Creative Commons
Fatemeh Sadat Toghraie, Maryam Bayat, Mahsa Sadat Hosseini

et al.

Cellular Oncology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 25, 2025

Tumor-infiltrating myeloid cells (TIMs), which encompass tumor-associated macrophages (TAMs), neutrophils (TANs), myeloid-derived suppressor (MDSCs), and dendritic (TADCs), are of great importance in tumor microenvironment (TME) integral to both pro- anti-tumor immunity. Nevertheless, the phenotypic heterogeneity functional plasticity TIMs have posed challenges fully understanding their complexity roles within TME. Emerging evidence suggested that presence is frequently linked prevention cancer treatment improvement patient outcomes survival. Given pivotal function TME, recently been recognized as critical targets for therapeutic approaches aimed at augmenting immunostimulatory cell populations while depleting or modifying those immunosuppressive. This review will explore important properties related immunity, angiogenesis, metastasis. We also document latest strategies targeting preclinical clinical settings. Our objective illustrate potential immunological may improve existing treatments.

Language: Английский

Citations

0
Myeloid-Derived Suppressor Cells: Implications in Cancer Immunology and Immunotherapy DOI Creative Commons
Juan F. Santibáñez

Frontiers in Bioscience-Landmark, Journal Year: 2025, Volume and Issue: 30(3)

Published: March 20, 2025

Myeloid-derived suppressor cells (MDSCs) are believed to be key promoters of tumor development and recognized as a hallmark cancer cells’ ability evade the immune system evasion. MDSC levels often increase in peripheral blood microenvironment (TME). These exert immunosuppressive functions, weakening anticancer surveillance system, part by repressing T-cell immunity. Moreover, MDSCs may promote progression interact with cells, increasing expansion favoring an immunotolerant TME. This review analyzes primary roles immunity, discusses urgent need develop effective MDSC-targeted therapies, highlights potential synergistic combination targeting chimeric antigen receptors checkpoint inhibitors.

Language: Английский

Citations

0
Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy DOI Creative Commons
Saber Imani, Reyhaneh Farghadani, Ghazaal Roozitalab

et al.

Journal of Experimental & Clinical Cancer Research, Journal Year: 2025, Volume and Issue: 44(1)

Published: April 25, 2025

Abstract This review discusses reprogramming the breast tumor immune microenvironment from an immunosuppressive cold state to immunologically active hot state. A complex interplay is revealed, in which accumulation of metabolic byproducts—such as lactate, reactive oxygen species (ROS), and ammonia—is shown impair T-cell function promote escape. It demonstrated that (TME) dominated by cytokines, including interleukin-10 (IL-10), transforming growth factorβ (TGFβ), IL-35. Notably, IL-35 produced regulatory T cells cancer cells. The conversion conventional into IL-35-producing induced cells, along with inhibition pro-inflammatory cytokine secretion, contributes suppression anti-tumor immunity. further key checkpoint molecules—such PD-1, PDL1, CTLA-4, TIM-3, LAG-3, TIGIT—are upregulated within TME, leading Tcell exhaustion diminished responses. blockade these checkpoints restore functionality proposed a strategy convert tumors ones robust effector cell infiltration. therapeutic potential chimeric antigen receptor (CAR)T therapy also explored, targeting specific tumor-associated antigens, such glycoproteins tyrosine kinases, highlighted. suggested CART efficacy can be enhanced combining inhibitors other immunomodulatory agents, thereby overcoming barriers imposed TME. Moreover, role microbiome regulating estrogen metabolism systemic inflammation reviewed. Alterations gut microbiota are affect microbiome-based interventions additional means facilitate cold-to-hot transition. concluded immunological pathways underpin suppression—through combination strategies involving blockade, therapies, modulation—the TME achieved. anticipated enhance infiltration function, improving overall immunotherapies better clinical outcomes for patients.

Language: Английский

Citations

0
Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment DOI

Eric Jou

Progress in molecular biology and translational science, Journal Year: 2024, Volume and Issue: unknown, P. 1 - 60

Published: Jan. 1, 2024

Language: Английский

Citations

0
FloraStilbene: immunotherapy adjuvant for breast cancer DOI Open Access

Famela Ramos,

Santosh Kesari,

George Delgado

et al.

Journal of Stem Cell Research & Therapeutics, Journal Year: 2024, Volume and Issue: 9(1), P. 45 - 53

Published: Jan. 1, 2024

Despite significant advancements in therapeutic approaches to triple-negative breast cancer, treatments remain relatively ineffective once metastasis occurs. The introduction of immunotherapy has revolutionized oncological therapies, yet hurdles before its full potential can be realized. In this review, we examine immune escape mechanisms shared between pregnancy (the 'fetal allograft') and cancer. We discuss the use abortion-inducing agents context cancer immunotherapy, also provide rationale preliminary data on FloraStilbene™, a combination polyphenol antioxidant pterostilbene glucocorticoid receptor antagonist mifepristone, for stimulation anticancer immunity.

Language: Английский

Citations

0